Development of a chaperone-mediated protein degrader targeting ERK5 that efficaciously reduces tumor growthCell Communication and SignalingIF8.92026-02-030OAAI
Mechanism of action of tumor-selective, chaperone-mediated protein degraders (CHAMPs)CANCER RESEARCHIF16.62024-03-220PRE
Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90 hetero-bifunctional small molecule therapeutic agentCANCER RESEARCHIF16.62024-03-220PRE
Tumor-selective, chaperone-mediated targeting of ERK5 (MAPK7)MOLECULAR CANCER THERAPEUTICSIF5.52023-12-010PRE
Treating KRAS(G12D) inhibitor resistance using a KRAS- and HSP90 chaperone-targeted hetero-bispecific small molecule agentMOLECULAR CANCER THERAPEUTICSIF5.52023-12-010PRE
Overcoming KRAS G12C inhibitor resistance with chaperone-mediated protein degrader in NSCLCMOLECULAR CANCER RESEARCHIF4.72023-05-010PRE
Chemically induced chaperone-mediated protein degradation (CHAMP) of KRAS(G12C)CANCER RESEARCHIF16.62023-04-040PRE
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项